Electrochemical interface based on polydopamine and gold nanoparticles/reduced graphene oxide for impedimetric detection of lung cancer cells

• Published in: RSC advances Vol. 13; no. 15; pp. 182 - 189
• Main Authors: Linh, Nguyen Dieu, Huyen, Nguyen Thi Trang, Dang, Nguyen Hai, Piro, Benoit, Thi Thu, Vu
• Format: Journal Article
• Language: English
• Published: England Royal Society of Chemistry 27.03.2023; The Royal Society of Chemistry
• Subjects: Biocompatibility; Carbonaceous materials; Charge transfer; Chemistry; Dopamine; Electrodes; Fluorine; Gold; Graphene; Interface stability; Interfaces; Lung cancer; Nanoparticles; Tin oxides
• ISSN: 2046-2069; 2046-2069
• DOI: 10.1039/d3ra00793f

The use of non-invasive approaches for monitoring therapy processes in cancer patients at late stages is truly needed. In this work, we aim to develop an electrochemical interface based on polydopamine combined with gold nanoparticles and reduced graphene oxide for impedimetric detection of lung cancer cells. Gold nanoparticles (around 75 nm) were dispersed onto reduced graphene oxide material pre-electrodeposited onto disposable fluorine doped tin oxide electrodes. The coordination between gold and carbonaceous material has somehow improved the mechanical stability of this electrochemical interface. Polydopamine was later introduced onto modified electrodes via self-polymerization of dopamine in an alkaline solution. The result has demonstrated the good adhesion and biocompatibility of polydopamine towards A-549 lung cancer cells. The presence of the two conductive materials (gold nanoparticles and reduced graphene oxide) has led to a six-times decrease in charge transfer resistance of polydopamine film. Finally, the as-prepared electrochemical interface was employed for impedimetric detection of A-549 cells. The detection limit was estimated to be only 2 cells per mL. These findings have proved the possibilities to use advanced electrochemical interfaces for point-of-care applications. Non-invasive approaches for monitoring therapy processes in cancer patients at late stages is truly needed.